BioInformant

Your Global Leader in Stem Cell Market Research

Venture Capital Funding Flowing into the iPSC Sector by Year

By Leave a Comment

The induced pluripotent stem cell (iPSC) sector has attracted strong venture capital funding in recent years, reflecting growing confidence in its potential across regenerative medicine, drug development, toxicology testing, personalized medicine, and disease modeling. From 2021 to 2024, numerous companies secured substantial investments, signaling a promising future for iPSC-based innovations.

This article examines key funding events in the sector, analyzing the scale of investments, their trajectory over time, and the companies driving industry growth. [Read more…]

Takara Bio Establishes Foothold in the Pluripotent Stem Cell Market

By 1 Comment

A few years back, Takara Bio Takara Bio Europeannounced that the Medical Products Agency (“MPA”), the Swedish national authority responsible for regulation of drug and medical products, had granted the company a manufacturing license for derivation and banking of human embryonic stem (hES) cells to be produced under GMP conditions. The cells were to be produced at Takara Bio’s manufacturing laboratory located in Göteborg, Sweden, within Takara Bio Europe’s facility.

This announcement made Takara Bio the first company worldwide to offer this service for human ESCs.

Takara Bio’s Role with Human Pluripotent Stem Cells

The significance of this event is that Takara Bio is capable of providing a predictable and reliable source of hES cells for future cellular therapeutic development by sourcing starting material from FDA-compliant facilities, according to FDA guidelines and leveraging its proprietary, feeder-free hES cell establishment method, which is animal- and human-component free. [Read more…]

Incucyte® CX3 System transforms continuous analysis of 3D cell models with confocal imaging and unmatched throughput

By Leave a Comment

  • New confocal fluorescence imaging minimizes photobleaching and phototoxicity effects, capturing clear images of live 3D culture
  • Industry-leading throughput enables real-time analysis of up to six microplates in parallel, maximizing data generation
  • Comprehensive, intuitive workflows with integrated data analysis empower every scientist to generate high-quality data from complex assays with greater speed and confidence

[Read more…]

Longeveron® Announces Licensing of New Cardiac Selective iPSC Technology for Cardiovascular Disease

By Leave a Comment

  • Longeveron has licensed issued US Patent 12,168,028 B2, entitled “Methods for obtaining cardiomyogenic precursor cells” from the University of Miami
  • New patent protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells (PSCs)
  • New technology substantially advances Longeveron’s repertoire of stem cell therapy technologies
  • Opportunity to expand pipeline in cardiovascular, rare and pediatric disease areas

[Read more…]

Japan Moves Toward Permitting Fertilized Embryo Research Using iPSC-Derived Eggs and Sperm

By Leave a Comment

A Japanese government bioethics panel has given the green light to a controversial but closely regulated area of research: the creation of human embryos using lab-generated sperm and eggs derived from pluripotent stem cells, including induced pluripotent stem (iPS) cells. The panel’s recommendation allows this practice strictly for scientific research focused on infertility and genetic diseases—not for reproductive purposes. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0